Plain-English translation of NCT07359846 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing whether , an investigational medication given as a shot under the skin, can help people with severe asthma that hasn't improved with standard treatments. You would receive either the new medication or a placebo injection every six months over one year, while researchers carefully track how your asthma responds. About 786 people will participate in this global trial.
Many people with severe asthma continue to have serious flare-ups even when taking strong medications. This trial is looking to see if this medication can reduce those flare-ups and help people breathe better.
You likely qualify if…
You likely don't qualify if…
You would visit the study site several times over about 14 months. First, you'd have screening visits 6–4 weeks before the study starts, then a run-in period to confirm you're a good fit. Starting at week zero, you'd receive either the new medication or placebo as a shot under your skin, with a second injection at week 26 (6 months). Throughout the year, you'd have regular check-ins to monitor your asthma control, lung function, and any side effects. After one year, you could choose to enter an optional extension where you'd continue receiving the medication for another several months.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
United States